- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00909519
Effect of Repeated Dosing of Naproxcinod on Renal Hemodynamic and on Sodium Balance in Healthy Volunteers Before and After a Single Dose of Furosemide
June 16, 2011 updated by: NicOx
A Phase 1, Single-Center, Randomized, Parallel-group, Placebo- and Naproxen- Controlled, Double-blind Study to Evaluate the Effect of Naproxcinod 750 mg Bid Administered for 8 Days on the Renal Hemodynamics, Natriuretic and Renin Responses to a Single Bolus IV Dose of Furosemide 40 mg in Male Healthy Normotensive Volunteers
This phase 1 study is an 8-day treatment period, randomized, controlled, double-blind, 3 parallel-groups, monocentric study.
The primary objective is to evaluate the effect of naproxcinod on the renal function when co-administered with furosemide in comparison to naproxen and placebo.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
31
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 33 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy, non smoker male subjects aged 18 and 35 years (inclusive), at the Screening visit.
- Body Mass Index (BMI) strictly between 18 and 30 kg/m² (inclusive) with body weight≥ 50 kg at the Screening visit.
- Normal physical examination at the Screening visit.
- Normal ECG (12-lead) at the Screening visit, as judged by the Investigator.
- At Screening and run-in period visits , Systolic Blood Pressure (SBP) between 100 and 139 mmHg (inclusive) and Diastolic Blood Pressure (DBP) between 50 and 89 mmHg (inclusive).
- At Screening and run-in period visits, HR between 45 and 90 bpm (inclusive).
- Subjects must be able to understand the written information sheet and informed consent and comply with all study requirements.
- Subjects must provide a written, dated and signed informed consent prior to any study procedure.
Exclusion Criteria:
- A history of hypersensitivity reactions (such as asthma, rhinitis, or urticaria) to aspirin, naproxen or any other NSAIDs; or hypersensitivity or contraindications to organic nitrate drugs or hypersensitivity to furosemide or to sinistrine or PAH.
- Family history of hypertension which may disqualify the subject, as judged by the investigator..
- History of any clinically relevant gastrointestinal (such as gastritis or gastric ulcer), respiratory, psychiatric, neurologic, kidney, liver, cardiac disease, bleeding disorder, other disease/condition or abnormal physical finding which may interfere with the study objectives. The investigator may disqualify any subject for a sound medical or psychiatric reason.
- History or presence of ASAT >40UI/L, ALAT >40UI/L, serum bilirubin 3 times above the Upper Limit of Normal range at the Screening visit.
- Creatinine clearance inferior/equal to 80 ml/min as calculated with the Cockcroft-Gault formula (Appendix 5 of the protocol) at the Screening visit.
- Plasmatic potassium <3.5 mmole/L at the Screening visit.
- Seropositivity for HBs, HBc, HIV 1 or HIV 2 at the Screening visit.
- Donations of blood, plasma or platelets within 3 months prior to the Screening visit or donation planned during the 3 months following Day 8.
- Any clinically significant abnormal laboratory values at the Screening visit.
- At the Screening visit, after 1 minute in a standing position, a drop of more than 20 mmHg in SBP or 10 mmHg in DBP or a clinical manifestation of postural hypotension.
- Chronic use of any drugs (prescription or OTC) within 4 weeks prior to Visit 2 (single use of medication such as paracetamol for headache will be tolerated at the lowest possible dose).
- Intake of any Nitric Oxide Synthase Inhibitor within 1 month before Screening visit.
- History of drug addiction or alcohol abuse as defined by DSM IVR, diagnostic criteria for drug and alcohol abuse or drug addiction.
- Positive drug screening (opiates, cannabinoids, cocaine, benzodiazepines, amphetamines, barbiturates) at the Screening visit.
- Current participation or participation within 60 days prior to the Screening visit, in another investigational study, including the present study or any previous enrolment in a naproxcinod study.
- In custody due to an administrative or a legal decision, or under tutelage, or being admitted to a sanitary or social institution.
- Any direct or indirect involvement with the study conduct or staff at site or any family link with study site staff.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: placebo
|
placebo
|
Active Comparator: naproxen
|
Naproxen 500 mg bid
|
Experimental: naproxcinod
|
furosemide
naproxcinod 750 mg bid
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the effect of naproxcinod on the renal function when co-administered with furosemide in comparison to naproxen and placebo
Time Frame: Day 8, between H3 and H9
|
Day 8, between H3 and H9
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
to assess the effect of naproxcinod on blood pressure (BP) in comparison with naproxen and placebo over 1 week and when co-administered with furosemide + to assess the general safety and tolerability
Time Frame: for over 1 week
|
for over 1 week
|
To evaluate the effect of naproxcinod when administered alone on renal function, after a week of administration, in comparison with naproxen and placebo.
Time Frame: Day 8 at H4
|
Day 8 at H4
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2009
Primary Completion (Actual)
April 1, 2009
Study Completion (Actual)
April 1, 2009
Study Registration Dates
First Submitted
May 27, 2009
First Submitted That Met QC Criteria
May 27, 2009
First Posted (Estimate)
May 28, 2009
Study Record Updates
Last Update Posted (Estimate)
June 17, 2011
Last Update Submitted That Met QC Criteria
June 16, 2011
Last Verified
June 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Natriuretic Agents
- Membrane Transport Modulators
- Diuretics
- Gout Suppressants
- Sodium Potassium Chloride Symporter Inhibitors
- Nitric Oxide Donors
- Furosemide
- Naproxen
- Naproxen-n-butyl nitrate
Other Study ID Numbers
- HCT3012-X-113
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Hemodynamics
-
Aarhus University HospitalCompletedCardiac Surgery | Anesthesia | Hemodynamics | Echocardiography | Phenylephrine | Ultrasonography, Renal | Renal PerfusionDenmark
-
Baystate Medical CenterCompletedRenal Failure | HemodynamicsUnited States
-
Cairo UniversityCompleted
-
Finn GustafssonCompleted
-
Cardinal HealthRecruitingHemodynamicsUnited States
-
Kepler University HospitalCompleted
-
AstesCompleted
-
Eye & ENT Hospital of Fudan UniversityRecruiting
-
Ajou University School of MedicineCompleted
-
Rabin Medical CenterCompleted
Clinical Trials on placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States